Alirocumab mechanism of action
Pro Research Analysisby 
Searched over 200M research papers
Alirocumab Mechanism of Action
Introduction to Alirocumab and PCSK9 Inhibition
Alirocumab is a monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein involved in cholesterol metabolism. By inhibiting PCSK9, alirocumab enhances the clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream, thereby reducing cardiovascular risk.
Mechanism of Action: Inhibition of PCSK9
Binding to LDL Receptors
Alirocumab works by binding to PCSK9, preventing it from attaching to LDL receptors on the surface of liver cells. Normally, PCSK9 binds to these receptors and promotes their degradation in lysosomes. By inhibiting this process, alirocumab increases the number of LDL receptors available to clear LDL-C from the blood Reyes-Soffer2015Watts2020Kühnast2014.
Effects on Lipoprotein Metabolism
Alirocumab significantly reduces LDL-C levels by increasing the fractional clearance rates (FCR) of LDL particles. This is achieved through an 80.4% increase in LDL-apoB FCR and a 23.9% reduction in LDL-apoB production rates (PR) . Additionally, alirocumab enhances the catabolism of intermediate-density lipoprotein (IDL) particles, further contributing to lower LDL-C levels .
Impact on Lipoprotein(a) and Apolipoprotein(a)
Dual Mechanism of Action
Alirocumab also lowers lipoprotein(a) [Lp(a)] levels, which are associated with increased cardiovascular risk. The reduction in Lp(a) is achieved through a dual mechanism: increasing the catabolism of Lp(a) particles and reducing their production Ying2022Watts2020Gaudet2016. Specifically, alirocumab increases the FCR of apolipoprotein(a) [apo(a)] by 28%, without significantly altering its production rate .
Clinical Implications
The reduction in Lp(a) levels by alirocumab is particularly beneficial for patients with elevated Lp(a) and those at high risk of atherosclerotic cardiovascular disease (ASCVD) Watts2020Gaudet2016. This effect is independent of other lipid-lowering therapies, such as statins, and contributes to the overall cardiovascular benefits of alirocumab Gaudet2016Bittner2020.
Effects on Atherosclerosis and Plaque Morphology
Reduction in Atherosclerotic Lesions
In animal models, alirocumab has been shown to significantly reduce the size and severity of atherosclerotic lesions. This is achieved through a dose-dependent decrease in total cholesterol and triglycerides, as well as an increase in hepatic LDL receptor protein levels . These changes lead to improved plaque morphology, characterized by increased smooth muscle cell and collagen content and decreased macrophage and necrotic core content .
Enhanced Effects with Statins
When used in combination with statins, alirocumab further enhances the reduction in cholesterol levels and atherosclerotic lesion size. This combination therapy also improves plaque stability, which is crucial for preventing cardiovascular events .
Conclusion
Alirocumab, by inhibiting PCSK9, significantly enhances the clearance of LDL-C and Lp(a) from the bloodstream. This is achieved through increased LDL receptor availability and enhanced catabolism of lipoprotein particles. The resulting reductions in LDL-C and Lp(a) levels contribute to the prevention of atherosclerosis and cardiovascular events, making alirocumab a valuable addition to lipid-lowering therapies.
Sources and full results
Most relevant research papers on this topic